Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -2.99% and Operating profit at -14.89% over the last 5 years
2
The company has declared Negative results for the last 4 consecutive quarters
3
With ROE of 5.18%, it has a very expensive valuation with a 1.42 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 15,776 Million (Large Cap)
27.00
NA
1.00%
0.44
5.48%
1.33
Revenue and Profits:
Net Sales:
8,819 Million
(Quarterly Results - Sep 2025)
Net Profit:
213 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.41%
0%
-6.41%
6 Months
-18.62%
0%
-18.62%
1 Year
-8.08%
0%
-8.08%
2 Years
-11.8%
0%
-11.8%
3 Years
-30.76%
0%
-30.76%
4 Years
-57.61%
0%
-57.61%
5 Years
-1.61%
0%
-1.61%
China Meheco Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.99%
EBIT Growth (5y)
-14.89%
EBIT to Interest (avg)
6.05
Debt to EBITDA (avg)
2.32
Net Debt to Equity (avg)
0.39
Sales to Capital Employed (avg)
1.93
Tax Ratio
28.46%
Dividend Payout Ratio
30.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.04%
ROE (avg)
8.92%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
1.42
EV to EBIT
23.23
EV to EBITDA
14.77
EV to Capital Employed
1.30
EV to Sales
0.65
PEG Ratio
NA
Dividend Yield
1.14%
ROCE (Latest)
5.58%
ROE (Latest)
5.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
8,818.60
8,813.10
0.06%
Operating Profit (PBDIT) excl Other Income
318.40
280.90
13.35%
Interest
23.20
53.00
-56.23%
Exceptional Items
0.00
5.70
-100.00%
Consolidate Net Profit
213.40
148.10
44.09%
Operating Profit Margin (Excl OI)
36.10%
16.90%
1.92%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 0.06% vs 6.66% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 44.09% vs -34.82% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
34,092.00
38,697.00
-11.90%
Operating Profit (PBDIT) excl Other Income
1,654.50
1,759.70
-5.98%
Interest
231.50
230.80
0.30%
Exceptional Items
-3.80
-33.30
88.59%
Consolidate Net Profit
686.60
1,242.10
-44.72%
Operating Profit Margin (Excl OI)
33.20%
33.10%
0.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -11.90% vs 3.25% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -44.72% vs 39.81% in Dec 2023
About China Meheco Group Co., Ltd. 
China Meheco Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






